胃不全麻痺の市場インサイト・疫学・市場予測(~2028)

◆英語タイトル:Gastroparesis Market Insights, Epidemiology, and Market Forecast—2028
◆商品コード:DATA00109020
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:193
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD6,250 ⇒換算¥718,750見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD18,750 ⇒換算¥2,156,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Gastroparesis Market Insights, Epidemiology, and Market Forecast—2028
DelveInsight’s ‘Gastroparesis Market Insights, Epidemiology, and Market Forecast—2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Gastroparesis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2028

Gastroparesis—Disease Understanding and Treatment Algorithm

Gastroparesis, which is a translated meaning of “stomach paralysis”, is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating. It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The overlap between the symptoms, of Gastroparesis and other disorders such as functional dyspepsia, makes the diagnosis of Gastroparesis difficult.

According to the American Diabetes Association, Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, in which the stomach takes too long to empty its contents (delayed gastric emptying). The vagus nerve controls the movement of food through the digestive tract. If this nerve is damaged or stops working, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Just as with other types of neuropathy, diabetes can damage the vagus nerve if blood glucose levels remain high over a long period. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves.

The etiology of Gastroparesis include diabetic, postsurgical, Iatrogenic, surgical and idiopathic as these are major causes of gastroparesis. Based on the causes, Gastroparesis is divided into three major types, i.e., Idiopathic gastroparesis, Diabetic gastroparesis, and Post-surgical gastroparesis. Some of the researchers proposed a classification system to help determine appropriate treatment options such as Grade 1, or mild gastroparesis, is characterized by symptoms that come and go and can easily be controlled by dietary modification and by avoiding medications that slow gastric emptying. Grade 2, or compensated gastroparesis, is characterized by moderately severe symptoms. Individuals with Grade 2 Gastroparesis are treated with medications that stimulate gastric emptying and medications that reduce vomiting; such individuals require hospitalization only infrequently. Grade 3, or gastric failure, is characterized by individuals who do not respond to medications used to treat gastroparesis. These individuals cannot maintain proper nutrition or hydration. Required therapies may include intravenous fluids and medications and nutrition, or surgery. Individuals with Grade 3 Gastroparesis often require hospitalization.

The treatment of Gastroparesis is based on the severity of symptoms of the disease. If diabetes is associated with gastroparesis, then treatment is done by controlling blood glucose levels. The treatment of Gastroparesis mainly includes nonpharmacological steps, such as dietary modification, and pharmacological measures, including medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery.

Gastroparesis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Gastroparesis, Gender-Specific Prevalence of Gastroparesis, Severity-Specific Prevalence of Gastroparesis, Type-Specific Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis] scenario of Gastroparesis in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2028.

DelveInsight’s analysts have assessed that the total prevalent population of Gastroparesis in the 7MM was 33,690,400 in 2017. In addition to this, it was accessed that the total diagnosed prevalent population of Gastroparesis in the 7MM was assessed to be 16,845,200 in 2017.

Gastroparesis Drug Chapters

Gastroparesis is a complex, debilitating dysmotility disorder with challenging symptom management. Given the limited efficacy of treatment options and serious side effects, significant research continues for therapeutic options for Gastroparesis.

The treatment landscape of Gastroparesis comprises of very few pharmacotherapies. The usual treatments for Gastroparesis include nutritional assessment, dietary modifications, and Pharmacological Therapies. Pharmacological therapies include Prokinetic Agents, Antiemetic Agents (off-label), and Antianxiety Benzodiazepine Agents (off-label). Apart from these Pharmacological therapies, Electrical Stimulation Therapies, Endoscopic Therapies, and Surgical Therapies are used for the treatment management of Gastroparesis. The primary aim of present therapies is to improve the efficiency of the gastric pump and to relieve symptoms of nausea, bloating, vomiting, and pain. The selection of recommended drugs is based on the severity of the symptoms (grades).

“According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Metoclopramide, Domperidone, Erythromycin, Antiemetics, Antidepressants, and Pain medicines are helpful for the treatment of Gastroparesis and associated symptoms.”

Gastroparesis Market Outlook

The market size of Gastroparesis in seven major markets (7MM) is estimated to be USD 3,414.16 million in 2017. The United States accounts for the highest market size of Gastroparesis,i.e. USD 1,558.41 million, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while the UK had the lowest market size of Gastroparesis in 2017.

Gastroparesis Drugs Uptake
With the launch of emerging therapies like Gimoti (EVK-001, a product of Evoke Pharma), which is a metoclopramide nasal spray, Relamorelin (Allergan), Tradipitant (Vanda Pharmaceuticals), Velusetrag (Theravance Biopharma), and CIN-102 (Deuterated Domperidone, CinRX Pharma), the market of Gastroparesis is anticipated to change during the forecast period (2019–2028).

Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by DelveInsight’s analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of Gastroparesis will have better management practices.

According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019–2028], and with their anticipated launch, the market size of Gastroparesis will also experience significant growth.

Gastroparesis Report Insights

• Total Prevalence of Gastroparesis
• Gender-Specific Prevalence of Gastroparesis
• Severity-Specific Prevalence of Gastroparesis
• Type-Specific Prevalence of Gastroparesis
• Total Diagnosed Prevalent Population of Gastroparesis
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Gastroparesis Report Key Strengths

• 10-Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Gastroparesis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Gastroparesis market
• Organize sales and marketing efforts by identifying the best opportunities for Gastroparesis market
• To understand the future market competition in the Gastroparesis market.

【レポートの目次】

1. Key Insights
2. Gastroparesis: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Gastroparesis in 2017
2.2. Total Market Share (%) Distribution of Gastroparesis in 2028
3. Gastroparesis: Disease Background and Overview
3.1. Introduction
3.2. Types of Gastroparesis: Based on Causes
3.2.1. Idiopathic Gastroparesis (IG)
3.2.2. Diabetic Gastroparesis (DGp)
3.2.3. Iatrogenic and Postsurgical Gastroparesis
3.3. Clinical Signs and Symptoms
3.4. Mechanisms or Pathophysiology of Gastroparesis
3.5. Diagnosis of Gastroparesis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalence of Gastroparesis in the 7MM
4.3. Type-Specific Prevalence of Gastroparesis in the 7MM
4.4. Gender-Specific Prevalence of Gastroparesis in the 7MM
4.5. Severity Specific Prevalence of Gastroparesis in the 7MM
4.6. Total Diagnosed Prevalent Population of Gastroparesis in the 7MM
5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalence of Gastroparesis in the United States
5.3. Type-Specific Diagnosed Prevalence of Gastroparesis in the United States
5.4. Gender-Specific Prevalence of Gastroparesis in the United States
5.5. Severity Specific Prevalence of Gastroparesis in the United States
5.6. Total Diagnosed Prevalence of Gastroparesis in the United States
6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Total Prevalence of Gastroparesis in Germany
6.1.2. Type-Specific Prevalence of Gastroparesis in Germany
6.1.3. Gender-Specific Prevalence of Gastroparesis in Germany
6.1.4. Severity Specific Prevalence of Gastroparesis in Germany
6.1.5. Total Diagnosed Prevalence of Gastroparesis in Germany
6.2. France Epidemiology
6.2.1. Total Prevalence of Gastroparesis in France
6.2.2. Type-Specific Prevalence of Gastroparesis in France
6.2.3. Gender-Specific Prevalence of Gastroparesis in France
6.2.4. Severity Specific Prevalence of Gastroparesis in France
6.2.5. Total Diagnosed Prevalence of Gastroparesis in France
6.3. Italy Epidemiology
6.3.1. Total Prevalence of Gastroparesis in Italy
6.3.2. Type-Specific Prevalence of Gastroparesis in Italy
6.3.3. Gender-Specific Prevalence of Gastroparesis in Italy
6.3.4. Severity Specific Prevalence of Gastroparesis in Italy
6.3.5. Total Diagnosed Prevalence of Gastroparesis in Italy
6.4. Spain Epidemiology
6.4.1. Total Prevalence of Gastroparesis in Spain
6.4.2. Type-Specific Prevalence of Gastroparesis in Spain
6.4.3. Gender-Specific Prevalence of Gastroparesis in Spain
6.4.4. Severity Specific Prevalence of Gastroparesis in Spain
6.4.5. Total Diagnosed Prevalence of Gastroparesis in Spain
6.5. United Kingdom Epidemiology
6.5.1. Total Prevalence of Gastroparesis in the United Kingdom
6.5.2. Type-Specific Prevalence of Gastroparesis in the United Kingdom
6.5.3. Gender-Specific Prevalence of Gastroparesis in the United Kingdom
6.5.4. Severity Specific Prevalence of Gastroparesis in the United Kingdom
6.5.5. Total Diagnosed Prevalence of Gastroparesis in the United Kingdom
7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalence of Gastroparesis in Japan
7.3. Type-Specific Prevalence of Gastroparesis in Japan
7.4. Gender-Specific Prevalence of Gastroparesis in Japan
7.5. Severity Specific Prevalence of Gastroparesis in Japan
7.6. Total Diagnosed Prevalence of Gastroparesis in Japan
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Treatment Algorithm for Gastroparesis
8.2. Treatment and Management for Gastroparesis
8.2.1. Dietary Modifications
8.2.2. Pharmacological Treatment
8.2.3. Pyloric Intervention
8.2.4. Gastric Electrical Stimulation
9. Proposed Clinical Guidelines for the Management of Gastroparesis
9.1. Recommendations
9.2. Consensus Guidelines for Clinical Management of Diabetic Gastroparesis
10. Unmet Needs
11. Marketed Products
11.1. Reglan: ANI Pharmaceuticals
11.1.1. Product Description
11.1.2. Regulatory Milestones
11.1.3. Product Profile
11.2. Motilium (Domperidone): Janssen
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Safety and Efficacy
11.2.4. Product Profile
12. Emerging Therapies
12.1. Key Cross Competition
12.2. Relamorelin: Allergan
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Product Profile
12.3. Gimoti (Metoclopramide Nasal Spray): Evoke Pharma
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.4. Tradipitant: Vanda Pharmaceuticals
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.4.5. Product Profile
12.5. Velusetrag: Theravance Biopharma
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. CNSA-001: Censa Pharmaceuticals
12.6.1. Product Description
12.6.2. Clinical Development
12.6.3. Product Profile
12.7. Nimacimab: Bird Rock Bio
12.7.1. Product Description
12.7.2. Other Development Activities
12.7.3. Clinical Development
12.7.4. Product Profile
12.8. CIN-102: CinDome Pharma
12.8.1. Product Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. TAK 906: Takeda (Millennium Pharmaceuticals)
12.9.1. Product Description
12.9.2. Other Developmental Activities
12.9.3. Clinical Development
12.9.4. Safety and Efficacy
12.9.5. Product Profile
13. Gastroparesis: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Size of Gastroparesis in 7MM
13.3. Market Size of Gastroparesis by Therapies in the 7MM
14. United States: Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of Gastroparesis in the United States
14.1.2. Market Size of Gastroparesis by Therapies in the US
15. EU-5 countries: Market Outlook
15.1. Germany Market Size
15.1.1. Total Market size of Gastroparesis in Germany
15.1.2. Market Size of Gastroparesis by therapies in Germany
15.2. France Market Size
15.2.1. Total Market size of Gastroparesis in France
15.2.2. Market Size of Gastroparesis by therapies in France
15.3. Italy Market Size
15.3.1. Total Market size of Gastroparesis in Italy
15.3.2. Market Size of Gastroparesis by therapies in Italy
15.4. Spain Market Size
15.4.1. Total Market size of Gastroparesis in Spain
15.4.2. Market Size of Gastroparesis by therapies in Spain
15.5. United Kingdom Market Size
15.5.1. Total Market size of Gastroparesis in the United Kingdom
15.5.2. Market Size of Gastroparesis by therapies in the UK
16. Japan Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of Gastroparesis in Japan
16.1.2. Market Size of Gastroparesis by therapies in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Table 1 Pathogenesis and Etiology of Gastroparesis
Table 2 Total Prevalence of Gastroparesis in the 7MM (2017–2028)
Table 3 Type-Specific Prevalence of Gastroparesis in the 7MM (2017–2028)
Table 4 Gender-Specific Prevalence of Gastroparesis in the 7MM (2017–2028)
Table 5 Severity-Specific Prevalence of Gastroparesis in the 7MM (2017–2028)
Table 6 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017–2028)
Table 7 Total Prevalence of Gastroparesis in the United States (2017–2028)
Table 8 Type-Specific Diagnosed Prevalence of Gastroparesis in the United States (2017–2028)
Table 9 Gender-Specific Prevalence of Gastroparesis in the US (2017–2028)
Table 10 Severity-Specific Prevalence of Gastroparesis in the United States(2017–2028)
Table 11 Total Diagnosed Prevalence of Gastroparesis in the United States (2017–2028)
Table 12 Total Prevalence of Gastroparesis in Germany (2017–2028)
Table 13 Type-Specific Prevalence of Gastroparesis in Germany (2017–2028)
Table 14 Gender-Specific Prevalence of Gastroparesis in Germany (2017–2028)
Table 15 Severity-Specific Prevalence of Gastroparesis in Germany (2017–2028)
Table 16 Total Diagnosed Prevalence of Gastroparesis in Germany (2017–2028)
Table 17 Total Prevalence of Gastroparesis in France (2017–2028)
Table 18 Type-Specific Prevalence of Gastroparesis in France (2017–2028)
Table 19 Gender-Specific Prevalence of Gastroparesis in France (2017–2028)
Table 20 Severity-Specific Prevalence of Gastroparesis in France (2017–2028)
Table 21 Total Diagnosed Prevalence of Gastroparesis in France (2017–2028)
Table 22 Total Prevalence of Gastroparesis in Italy (2017–2028)
Table 23 Type-Specific Prevalence of Gastroparesis in Italy (2017–2028)
Table 24 Gender-Specific Prevalence of Gastroparesis in Italy (2017–2028)
Table 25 Severity-Specific Prevalence of Gastroparesis in Italy (2017–2028)
Table 26 Total Diagnosed Prevalence of Gastroparesis in Italy (2017–2028)
Table 27 Total Prevalence of Gastroparesis in Spain (2017–2028)
Table 28 Type-Specific Prevalence of Gastroparesis in Spain (2017–2028)
Table 29 Gender-Specific Prevalence of Gastroparesis in Spain (2017–2028)
Table 30 Severity-Specific Prevalence of Gastroparesis in Spain (2017–2028)
Table 31 Total Diagnosed Prevalence of Gastroparesis in Spain (2017–2028)
Table 32 Total Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Table 33 Type-Specific Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Table 34 Gender-Specific Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Table 35 Severity-Specific Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Table 36 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Table 37 Total Prevalence of Gastroparesis in Japan (2017–2028)
Table 38 Type-Specific Prevalence of Gastroparesis in Japan (2017–2028)
Table 39 Gender-Specific Prevalence of Gastroparesis in Japan (2017–2028)
Table 40 Severity-Specific Prevalence of Gastroparesis in Japan (2017–2028)
Table 41 Total Diagnosed Prevalence of Gastroparesis in Japan (2017–2028)
Table 42 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
Table 43 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
Table 44 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
Table 45 Emerging Keycross Competition
Table 46 Relamorelin (RM-131), Clinical Trial Description, 2019
Table 47 Metoclopramide Nasal Spray; Clinical Trial Description, 2019
Table 48 Tradipitant; Clinical Trial Description, 2019
Table 49 Velusetrag; Clinical Trial Description, 2019
Table 50 CNSA-001, Clinical Trial Description, 2019
Table 51 Nimacimab, Clinical Trial Description, 2019
Table 52 CIN-102, Clinical Trial Description, 2019
Table 53 TAK 906, Clinical Trial Description, 2019
Table 54 Market Size of Gastroparesis in 7MM in USD Million (2017–2028)
Table 55 Market Size of Gastroparesis by therapies in the 7MM, in USD Million (2017–2028)
Table 56 Currently Prescribed Classes and their Side-Effects
Table 57 Emerging Therapies Expected to be Launched During Forecast Period (2019–2028) in the United States
Table 58 The US Market Size of Gastroparesis in USD Million (2017–2028)
Table 59 Market Size of Gastroparesis by therapies in the US, in USD Million (2017–2028)
Table 60 Germany Market Size of Gastroparesis in USD Million (2017–2028)
Table 61 Market Size of Gastroparesis by therapies in Germany, in USD Million (2017–2028)
Table 62 France Market Size of Gastropares is in USD Million (2017–2028)
Table 63 Market Size of Gastroparesis by therapies in France, in USD Million (2017–2028)
Table 64 Italy Market Size of Gastroparesis in USD Million (2017–2028)
Table 65 Market Size of Gastroparesis by therapies in Italy, in USD Million (2017–2028)
Table 66 Spain Market Size of Gastroparesis in USD Million (2017–2028)
Table 67 Market Size of Gastroparesis by therapies in Spain, in USD Million (2017–2028)
Table 68 The UK Market Size of Gastroparesis in USD Million (2017–2028)
Table 69 Market Size of Gastroparesis by therapies in the UK, in USD Million (2017–2028)
Table 70 Japan Market Size of Gastroparesis in USD Million (2017–2028)
Table 71 Market Size of Gastroparesis by therapies in Japan, in USD Million (2017–2028)
Figure 1 Types of Gastroparesis Based on Causes
Figure 2 Etiologies of Gastroparesis
Figure 3 Interaction of Interstitial Cells of Cajal (ICC) Cells and Neuronal Nitric Oxide Synthase (nNOS) Signaling for Normal Gastric Emptying (GE)
Figure 4 Mechanisms of Gastric Accommodation and Emptying
Figure 5 Diagnosis of Gastroparesis
Figure 6 Total Prevalence of Gastroparesis in the 7MM (2017–2028)
Figure 7 Type-Specific Prevalence of Gastroparesis in the 7MM (2017–2028)
Figure 8 Gender- Specific Prevalence of Gastroparesis in the 7MM(2017–2028)
Figure 9 Severity-Specific Prevalence of Gastroparesis in the 7MM (2017–2028)
Figure 10 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017–2028)
Figure 11 Total Prevalence of Gastroparesis in the United States (2017–2028)
Figure 12 Type-Specific Diagnosed Prevalence of Gastroparesis in the United States (2017–2028)
Figure 13 Gender- Specific Prevalence of Gastroparesisin the US (2017–2028)
Figure 14 Severity-Specific Prevalence of Gastroparesis in the United States (2017–2028)
Figure 15 Total Diagnosed Prevalence of Gastroparesis in the United States (2017–2028)
Figure 16 Total Prevalence of Gastroparesis in Germany (2017–2028)
Figure 17 Type-Specific Prevalence of Gastroparesis in Germany (2017–2028)
Figure 18 Gender- Specific Prevalence of Gastroparesis in Germany (2017–2028)
Figure 19 Severity-Specific Prevalence of Gastroparesis in Germany (2017–2028)
Figure 20 Total Diagnosed Prevalence of Gastroparesis in Germany (2017–2028)
Figure 21 Total Prevalence of Gastroparesis in France (2017–2028)
Figure 22 Type-Specific Prevalence of Gastroparesis in France (2017–2028)
Figure 23 Gender- Specific Prevalence of Gastroparesis in France (2017–2028)
Figure 24 Severity-Specific Prevalence of Gastroparesis in France (2017–2028)
Figure 25 Total Diagnosed Prevalence of Gastroparesis in France (2017–2028)
Figure 26 Total Prevalence of Gastroparesis in Italy (2017–2028)
Figure 27 Type-Specific Prevalence of Gastroparesis in Italy (2017–2028)
Figure 28 Gender- Specific Prevalence of Gastroparesis in Italy (2017–2028)
Figure 29 Severity-Specific Prevalence of Gastroparesis in Italy (2017–2028)
Figure 30 Total Diagnosed Prevalence of Gastroparesis in Italy (2017–2028)
Figure 31 Total Prevalence of Gastroparesis in Spain (2017–2028)
Figure 32 Type-Specific Prevalence of Gastroparesis in Spain (2017–2028)
Figure 33 Gender- Specific Prevalence of Gastroparesis in Spain (2017–2028)
Figure 34 Severity-Specific Prevalence of Gastroparesis in Spain (2017–2028)
Figure 35 Total Diagnosed Prevalence of Gastroparesis in Spain (2017–2028)
Figure 36 Total Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Figure 37 Type-Specific Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Figure 38 Gender- Specific Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Figure 39 Severity-Specific Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Figure 40 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017–2028)
Figure 41 Total Prevalence of Gastroparesis in Japan (2017–2028)
Figure 42 Type-Specific Prevalence of Gastroparesis in Japan (2017–2028)
Figure 43 Gender- Specific Prevalence of Gastroparesis in Japan (2017–2028)
Figure 44 Severity-Specific Prevalence of Gastroparesis in Japan (2017–2028)
Figure 45 Total Diagnosed Prevalence of Gastroparesis in Japan (2017–2028)
Figure 46 Diagnosis and Management Algorithm for Gastroparesis Syndromes
Figure 47 Algorithm for Prokinetic Therapy in Gastroparesis
Figure 48 Treatment Algorithm for Gastroparesis
Figure 49 Unmet Needs of Gastroparesis
Figure 50 Potential Drug-drug Interactions in Gastroparesis
Figure 51 Market Size of Gastroparesis in the 7MM in USD Million (2017–2028)
Figure 52 Market Size of Gastroparesis by therapies in the 7MM, in USD Million (2017–2028)
Figure 53 Market Size of Gastroparesis in the US, USD Millions (2017–2028)
Figure 54 Market Size of Gastroparesis by therapies in the United States, in USD Million (2017–2028)
Figure 55 Market Size of Gastroparesis in Germany, USD Millions (2017–2028)
Figure 56 Market Size of Gastroparesis by therapies in Germany, in USD Million (2017–2028)
Figure 57 Market Size of Gastroparesis in France, USD Millions (2017–2028)
Figure 58 Market Size of Gastroparesis by therapies in France, in USD Million (2017–2028)
Figure 59 Market Size of Gastroparesis in Italy, USD Millions (2017–2028)
Figure 60 Market Size of Gastroparesis by therapies in Italy in USD Million (2017–2028)
Figure 61 Market Size of Gastroparesis in Spain, USD Millions (2017–2028)
Figure 62 Market Size of Gastroparesis by therapies in Spain in USD Million (2017–2028)
Figure 63 Market Size of Gastroparesis in the UK, USD Millions (2017–2028)
Figure 64 Market Size of Gastroparesis by therapies in the UK in USD Million (2017–2028)
Figure 65 Market Size of Gastroparesis in Japan, USD Millions (2017–2028)
Figure 66 Market Size of Gastroparesis by therapies in Japan in USD Million (2017–2028)
Figure 67 Market Drivers
Figure 68 Market Barriers



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[胃不全麻痺の市場インサイト・疫学・市場予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆